Our result, i.e. overexpression of FGF-10 gene in more than 50 % of all tumors in stage III and in 50 % of all positive lymph invasion patients, reflects the importance of this factor in both progression and targeted therapy of colorectal cancer. This evidence concerns the gene FGF10 and colorectal cancer.